Please find attached our forecast of Loss of Exclusivities
in US between 2026 through 2028.
Despite severe competition, the Para IV space still continues to attract all major generic manufacturers globally. As a result, ~$53 bn of sales will lose its exclusivity over next 3 years, including Eliquis (Apixaban) with $9.3 bn in sales.
While Teva continues to file the highest number of Para IV products with almost twice the number of FTFs than its immediate next, overall Indian manufacturers continue to dominate the space accounting for 7 out of the top 10 Para IV filers.
Interestingly, competitive intensity among Para IV Filers is reducing with the share of sole FTF holders rising significantly from 2026 to 2028.